Navigation Links
AspenBio Pharma to Provide Shareholders with Business Update
Date:8/8/2012

CASTLE ROCK, Colo., Aug. 8, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, announced that it will begin hosting regular conference calls to provide its investors and the broader investment and medical communities with timely updates on the Company's business and anticipated milestones.  AspenBio's senior management will host a conference call and live audio webcast on Wednesday, August 15, 2012, at 5:00 p.m. ET to discuss recent activities and upcoming plans for the clinical development and potential commercialization of AppyScore™.  

Interested participants and investors may access the conference call by dialing (800) 860-2442 (U.S./Canada) or (412) 858-4600 (international).  An audio webcast will be accessible via the Investors Relations section of the AspenBio web site, www.aspenbiopharma.com.  

A telephonic replay of the call will be available for two weeks beginning at 8:00 p.m. ET on August 15, 2012.  Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10017298.  The webcast replay will remain available in the Investors Relations section of the AspenBio web site for 30 days.

About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its lead product, AppyScoreAppyScore is a unique blood-based test with projected high sensitivity and negative predictive value that is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  AppyScore is initially being developed for pediatric, adolescent and young adult patients with abdominal pain as this population is at the highest risk for appendicitis as well having the highest risk of the long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Final Prospectus filed on June 20, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com

 


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
2. AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
3. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
4. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
6. Online Pharmacy Domain Policy Changes Announced by ICANN Registrar Internet.bs Corp.
7. Jazz Pharmaceuticals Announces Second Quarter 2012 Results
8. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
9. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
10. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
11. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet ... in musculoskeletal healthcare, today announced it has earned a ... of 2017" list. The Company was ranked among 500 ... Large Employers and Healthcare Equipment and Services. ... based on an anonymous, independent survey of over 30,000 ...
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration ... from its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of ... District had left education officials with a number of critical issues to address before ... had to be accomplished with little or no disruption to class schedules. Second, the ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, ... in New York City. He is known for his distinguished expertise and experience in ... Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and Chris ... spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation continuing ... the program, private practitioners receive cutting-edge clinical training and learn how to perform ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT OPPOSING PRESIDENT DONALD ... to Donald Trump’s budget, “A New Foundation for American Greatness—President's Budget FY 2018,” ... poor, marginalizes underserved populations, undermines productivity, and destroys the social safety net needed ...
Breaking Medicine News(10 mins):